Pretomanid
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Pretomanid: From Multidrug-Resistant Tuberculosis to Candidiasis
One-Sentence Summary
Pretomanid is a nitroimidazooxazine antimycobacterial, used as part of the BPaL/BPaLM regimen (bedaquiline, pretomanid, linezolid ± moxifloxacin) for extensively drug-resistant and treatment-intolerant/non-responsive multidrug-resistant pulmonary tuberculosis. The TxGNN model predicts it may be effective for Candidiasis, but this is a pure model prediction with no supporting clinical trials or literature, and the evidence pack’s own mechanistic review flags it as biologically implausible.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Multidrug-/extensively drug-resistant pulmonary tuberculosis (as part of the BPaL/BPaLM regimen) — not captured in structured taiwan_regulatory data |
| Predicted New Indication | Candidiasis |
| TxGNN Prediction Score | 99.69% |
| Evidence Level | L5 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Pretomanid is not available in this evidence pack (flagged as a High-severity data gap). Based on known information, Pretomanid is a nitroimidazooxazine prodrug that requires activation by the mycobacteria-specific deazaflavin-dependent nitroreductase (Ddn)/F420 cofactor system to exert its bactericidal effect — a pathway specific to the Mycobacterium genus.
Candida species do not possess this Ddn/F420 activation pathway, and there is no known antifungal mechanism for Pretomanid. The evidence pack’s own mechanistic assessment explicitly notes that this prediction reflects knowledge-graph similarity rather than biological plausibility, and that it lacks a credible pharmacological rationale.
For context, other top-ranked TxGNN candidates in this evidence pack (leprosy, coronary artery disease, myocardial ischemia, ALCAPA) were reviewed under the same lens: leprosy has some genus-level mechanistic logic (both M. leprae and M. tuberculosis are mycobacteria) but is directly contradicted by in vitro evidence showing M. leprae is naturally resistant to PA-824/Pretomanid; the cardiovascular predictions have no plausible mechanism and instead run counter to Pretomanid’s known QT-prolongation risk. None of the candidates in this pack currently clear a basic mechanistic plausibility bar.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Denmark Market Information
Pretomanid currently holds no marketing authorisation in Denmark (0 licenses; market status: not marketed).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Note: structured key_warnings, contraindications, and DDI data were not available for this evidence pack (query status: not_found). Separately, the evidence pack’s mechanistic notes for other predicted indications reference a known QT-prolongation signal for Pretomanid — this should be confirmed against the SmPC before any further evaluation.
Conclusion and Next Steps
Decision: Hold
Rationale: The candidiasis prediction is supported only by a TxGNN similarity score (L5, no clinical trials, no literature), and the pack’s own mechanistic review finds no plausible antifungal pathway for a mycobacteria-specific prodrug. Combined with a Blocking-severity data gap on SmPC warnings/contraindications, this candidate does not meet the threshold to advance past S0.
To proceed, the following is needed:
- TFDA/Danish SmPC label data (warnings, contraindications) — currently a Blocking data gap (DG001)
- Confirmed mechanism of action (DG001/DG002) to properly assess relevance to any non-mycobacterial indication
- Any in vitro or preclinical evidence of Pretomanid activity against Candida species before further investment
- If the leprosy signal is of interest instead, note it is directly contradicted by existing in vitro resistance data (PMID 17005816) and would also require dedicated re-evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.